TKT to Present At SG Cowen's Fifth Annual Global Health Care Conference
November 09 2004 - 8:35AM
PR Newswire (US)
TKT to Present At SG Cowen's Fifth Annual Global Health Care
Conference CAMBRIDGE, Mass., Nov. 9 /PRNewswire-FirstCall/ --
Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that
the company will present at SG Cowen's 5th Annual Global Health
Care Conference being held in Geneva, Switzerland, November 16-17,
2004. Michael J. Astrue, President and Chief Executive Officer will
present an overview of TKT's business activities and product
pipeline at 10:20 a.m. Central European Time on Tuesday, November
16, 2004. A live audio webcast of this presentation will be
available at http://www.tktx.com/ on TKT's Investor Information
website under the Events category. A replay will be available for
approximately 30 days after the webcast. About TKT Transkaryotic
Therapies, Inc. is a biopharmaceutical company primarily focused on
researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the
company markets Replagal(TM), an enzyme replacement therapy for
Fabry disease, and is developing treatments for Hunter syndrome and
Gaucher disease. In addition to its focus on rare diseases, TKT
intends to commercialize Dynepo(TM), its Gene- Activated(R)
erythropoietin product for anemia related to kidney disease, in the
European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe,
Canada and South America. Additional information about TKT is
available on the company's website at http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a
trademark of Sanofi-Aventis SA. Contact: Daniella M. Lutz Corporate
Communications Manager (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of
TKT, +1- 617-349-0205 Web site: http://www.tktx.com/ Company News
On-Call: http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Oct 2023 to Oct 2024